{"nctId":"NCT02514772","briefTitle":"GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera®","startDateStruct":{"date":"2015-07"},"conditions":["Rheumatoid Arthritis"],"count":107,"armGroups":[{"label":"GP2013 - proposed biosimilar rituximab","type":"EXPERIMENTAL","interventionNames":["Biological: GP2013 - A Proposed biosimilar rituximab"]},{"label":"Originator rituximab - Rituxan ® or MabThera ®","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Originator rituximab - Rituxan ® or MabThera ®"]}],"interventions":[{"name":"GP2013 - A Proposed biosimilar rituximab","otherNames":[]},{"name":"Originator rituximab - Rituxan ® or MabThera ®","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of rheumatoid arthritis (RA) according to ACR 2010 criteria\n* Completed one full treatment course with either Rituxan® or MabThera®\n* Eligible for a further treatment course with Rituxan® or MabThera®- Currently treated with methotrexate\n\nExclusion Criteria:\n\n* RA functional status class IV (ACR 1991 revised criteria)\n* Systemic manifestation of RA\n* Positive serology for hepatitis B or hepatitis C infection\n* Active systemic infection\n* History of cancer\n* Known severely immunocompromised state\n\nOther protocol-defined inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Patients Experiencing Anaphylactic Reactions","description":"2006 NIAID/FAAN\\* criteria were used for identification of anaphylactic reactions within 24h of each study drug infusion.\n\nFor patients with no history of infusion-related reactions during their previous treatments with rituximab, symptoms/signs in at least 2 out of 4 organ systems:\n\n* Skin/mucosal tissue\n* Respiratory organs\n* Drop of systolic blood pressure (\\<90 mmHg or variance from baseline \\>30%) or associated symptoms\n* Gastrointestinal organs were defined as an anaphylactic reaction.\n\nThe same criteria were also applied to patients with history of infusion-related reactions during their previous treatments with rituximab. In addition, if these patients experienced only a rapid drop in systolic blood pressure (\\<90 mmHg or variance from baseline \\>30%), this was defined as an anaphylactic reaction disregarding involvement of other organ systems.\n\n\\* NIAID - National Institute of Allergy and Infectious Diseases FAAN - Food Allergy and Anaphylaxis Network","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Patients Experiencing Hypersensitivity Reactions","description":"The standardized MedDRA query (SMQ) - Hypersensitivity reactions (SMQ 20000214) was used for the identification of hypersensitivity reactions overall from first infusion in the adverse event database.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"PRIMARY","title":"Immunogenicity","description":"Number of patients tested positive for anti-drug-antibodies (ADA) post-randomization.\n\nPatients with negative ADA results at screening and at least one evaluable post-randomization ADA assessment are included in the analysis","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Patients Experiencing Potential Infusion-Related Reactions","description":"Patients, experienced infusion related reactions repeatedly (i.e. during the first and second infusion) are counted only once in the overall line.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":53},"commonTop":["Bronchitis","Upper respiratory tract infection","Rheumatoid arthritis","Headache","Nausea"]}}}